Hyderabad-based NATCO Pharma Ltd has announced that its co-development and marketing partner, Dr Reddy’s Laboratories Ltd, has filed for registration of doxorubicin hydrochloride liposome injection for intravenous use, in the European markets.
It is the therapeutic equivalent generic version of Janssen’s brand, Doxil, which is predominantly used for the treatment of metastatic breast cancer, advanced ovarian cancer and progressive multiple myeloma.
The Doxil brand, 2mg/ml, had sales of approximately $130.5 million in Europe for the 12 months ending December 31, 2017, according to Quintiles IMS.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.